Maspin and Suppression of Tumor Metastasis

  • Lauren Reinke
  • Ming Zhang


Maspin is a member of the family of Serine Protease Inhibitors or serpins. Since its discovery in 1994, considerable amount of information has been gathered regarding its role in normal tissue development and pathological processes, such as tumorigenesis and metastasis. It is now well recognized that maspin is unique serpin with tumor suppressing activities. Like many of its serpin family members, maspin possesses multiple functions, including antimigration, anti-invasion, induction of apoptosis, and anti-angiogenesis. Its functions are dependent on its cellular locations: extracellular, intracellular, mitochondria, and nucleus. This chapter covers three major topics on maspin research: biological functions of maspin, regulation of maspin gene expression, and modeling breast cancers in mice with maspin as a paradigm. Our goal is to provide readers with a comprehensive analysis of maspin study by many maspin researchers in the past few years and also with unique insights on our study of maspin functions in mouse model in vivo.


Mammary Tumor Mammary Epithelial Cell Maspin Expression Normal Mammary Epithelial Cell Sensitize Breast Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Affara NI, Coussens LM (2007) IKKalpha at the crossroads of inflammation and metastasis. Cell 129:25–26PubMedCrossRefGoogle Scholar
  2. Al-Ayyoubi M, Gettins PG, Volz K (2004) Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained. J Biol Chem 279:55540–55544PubMedCrossRefGoogle Scholar
  3. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z, Hendrix MJ (2005) Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther 4:400–406PubMedCrossRefGoogle Scholar
  4. Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan N, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC, Hendrix MJ (2005) Maspin binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem 280(40):34210–34217PubMedCrossRefGoogle Scholar
  5. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ (2006) Biological functions of maspin. J Cell Physiol 209:617–624PubMedCrossRefGoogle Scholar
  6. Biliran H Jr, Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61:8676–8682PubMedGoogle Scholar
  7. Blacque OE, Worrall DM (2002) Evidence for a direct interaction between the tumour suppressor serpin maspin, and types I and III collagen. J Biol Chem 277(13):10783–10788PubMedCrossRefGoogle Scholar
  8. Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC, Rochefort H (1997) Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer 79:2132–2136PubMedCrossRefGoogle Scholar
  9. Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar G, Rochefort H (1989) Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res 49:3904–3909PubMedGoogle Scholar
  10. Cella N, Contreras A, Latha K, Rosen JM, Zhang M (2006) Maspin is physically associated with [beta]1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J 20:1510–1512PubMedCrossRefGoogle Scholar
  11. Costello JF, Vertino PM (2002) Methylation matters: a new spin on maspin. Nat Genet 31:123–124PubMedCrossRefGoogle Scholar
  12. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37PubMedCrossRefGoogle Scholar
  13. Domann FE, Rice JC, Hendrix MJ, Futscher BW (2000) Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 85:805–810PubMedCrossRefGoogle Scholar
  14. Dyson N, Buchkovich K, Whyte P, Harlow E (1989) The cellular 107 K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 58:249–255PubMedCrossRefGoogle Scholar
  15. Ferrucci PF, Rabascio C, Gigli F, Corsini C, Giordano G, Bertolini F, Martinelli G (2007) A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 30:955–962PubMedGoogle Scholar
  16. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE (2002) Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 31:175–179PubMedCrossRefGoogle Scholar
  17. Hall DC, Johnson-Pais TL, Grubbs B, Bernal R, Leach RJ, Padalecki SS (2008) Maspin reduces prostate cancer metastasis to bone. Urol Oncol 26(6):652–658PubMedCrossRefGoogle Scholar
  18. Hellgren I, Drvota V, Pieper R, Enoksson S, Blomberg P, Islam KB, Sylven C (2000) Highly ­efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo studies. Cell Mol Life Sci 57:1326–1333PubMedCrossRefGoogle Scholar
  19. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923–926PubMedCrossRefGoogle Scholar
  20. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S (2002) Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 21:4089–4098PubMedCrossRefGoogle Scholar
  21. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431–436PubMedCrossRefGoogle Scholar
  22. Kelly WK, Marks PA (2005) Drug insight: histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2:150–157PubMedCrossRefGoogle Scholar
  23. Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA, Gruman LM, Seftor RE, Norwood LE, Hendrix MJ (2004) Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res 10:449–454PubMedCrossRefGoogle Scholar
  24. Khalkhali-Ellis Z, Hendrix MJ (2003) Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. Am J Pathol 162:1411–1417PubMedCrossRefGoogle Scholar
  25. Khalkhali-Ellis Z, Hendrix MJ (2007) Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res 67:3535–3539PubMedCrossRefGoogle Scholar
  26. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF et al (2005) Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65:7370–7377PubMedCrossRefGoogle Scholar
  27. Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, Howard E, de Lima RL, Daack-Hirsch S, Sander A et al (2002) Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet 32:285–289PubMedCrossRefGoogle Scholar
  28. Latha K, Zhang W, Cella N, Shi HY, Zhang M (2005) Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 25:1737–1748PubMedCrossRefGoogle Scholar
  29. Law RH, Irving JA, Buckle AM, Ruzyla K, Buzza M, Bashtannyk-Puhalovich TA, Beddoe TC, Nguyen K, Margaret Worrall D, Bottomley SP et al (2005) The high resolution crystal structure of the human tumour suppressor maspin reveals a novel conformational switch in the G-helix. J Biol Chem 280(23):22356–22364PubMedCrossRefGoogle Scholar
  30. Li M, Hu J, Heermeier K, Hennighausen L, Furth PA (1996) Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells. Cell Growth Differ 7:3–11PubMedGoogle Scholar
  31. Li M, Lewis B, Capuco AV, Laucirica R, Furth PA (2000) WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 19:1010–1019PubMedCrossRefGoogle Scholar
  32. Li X, Yin S, Meng Y, Sakr W, Sheng S (2006) Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res 66:9323–9329PubMedCrossRefGoogle Scholar
  33. Li Z, Schem C, Shi YH, Medina D, Zhang M (2008) Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis 25(4):389–400PubMedCrossRefGoogle Scholar
  34. Li Z, Shi HY, Zhang M (2005) Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene 24(12):2008–2019PubMedCrossRefGoogle Scholar
  35. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prebois C, Rochefort H, Vignon F (2006) Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 237:167–179PubMedCrossRefGoogle Scholar
  36. Liotta LA, Rao CN, Barsky SH (1983) Tumor invasion and the extracellular matrix. Lab Invest 49:636–649PubMedGoogle Scholar
  37. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690–694PubMedCrossRefGoogle Scholar
  38. Maass N, Hojo T, Zhang M, Sager R, Jonat W, Nagasaki K (2000) Maspin – a novel protease inhibitor with tumor-suppressing activity in breast cancer. Acta Oncol 39:931–934PubMedCrossRefGoogle Scholar
  39. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, Licht JD, Ishii S (2008) ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene 27:1045–1054PubMedCrossRefGoogle Scholar
  40. McCormick F (2001) Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1:130–141PubMedCrossRefGoogle Scholar
  41. Medina D (1996) The mammary gland: a unique organ for the study of development and tumorigenesis. J Mammary Gland Biol Neoplasia 1:5–19PubMedCrossRefGoogle Scholar
  42. Medina D, Daniel C (1996) Experimental models of development, function, and neoplasia. J Mammary Gland Biol Neoplasia 1:3–4PubMedCrossRefGoogle Scholar
  43. Mietz JA, Unger T, Huibregtse JM, Howley PM (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013–5020PubMedGoogle Scholar
  44. Ng IO, Lai EC, Ng MM, Fan ST (1992) Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer 70:45–49PubMedCrossRefGoogle Scholar
  45. O’Brien T, Karlsen AE, Andersen HU, Mandrup-Poulsen T, Nerup J (1999) Absence of toxicity associated with adenoviral-mediated transfer of the beta-galactosidase reporter gene to neonatal rat islets in vitro. Diabetes Res Clin Pract 44:157–163PubMedCrossRefGoogle Scholar
  46. Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Amir S, Seftor RE, Seftor EA, Hendrix MJ (2003) Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2:398–403PubMedGoogle Scholar
  47. Pemberton PA, Wong DT, Gibson HL, Kiefer MC, Fitzpatrick PA, Sager R, Barr PJ (1995) The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. J Biol Chem 270:15832–15837PubMedCrossRefGoogle Scholar
  48. Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, Sheng S (2002) Maspin is up-regulated in premalignant prostate epithelia. Prostate 53:255–262PubMedCrossRefGoogle Scholar
  49. Pillai R, Coverdale LE, Dubey G, Martin CC (2004) Histone deacetylase 1 (HDAC-1) required for the normal formation of craniofacial cartilage and pectoral fins of the zebrafish. Dev Dyn 231:647–654PubMedCrossRefGoogle Scholar
  50. Rahman Q, Abidi P, Afaq F, Schiffmann D, Mossman BT, Kamp DW, Athar M (1999) Glutathione redox system in oxidative lung injury. Crit Rev Toxicol 29:543–568PubMedCrossRefGoogle Scholar
  51. Ren WP, Sloane BF (1996) Cathepsins D and B in breast cancer. Cancer Treat Res 83:325–352PubMedCrossRefGoogle Scholar
  52. Rochlitz CF (2001) Gene therapy of cancer. Swiss Med Wkly 131:4–9PubMedGoogle Scholar
  53. Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89:21–39PubMedCrossRefGoogle Scholar
  54. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJ, Pemberton P et al (1994) RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb Symp Quant Biol 59:537–546PubMedGoogle Scholar
  55. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R (1996) Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 93:11669–11674PubMedCrossRefGoogle Scholar
  56. Sherman JM, Stone EM, Freeman-Cook LL, Brachmann CB, Boeke JD, Pillus L (1999) The conserved core of a human SIR2 homologue functions in yeast silencing. Mol Biol Cell 10:3045–3059PubMedGoogle Scholar
  57. Shi HY, Liang R, Templeton NS, Zhang M (2002) Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol Ther 5:755–761PubMedCrossRefGoogle Scholar
  58. Shi HY, Stafford LJ, Liu Z, Liu M, Zhang M (2007) Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase. Cell Motil Cytoskeleton 64:338–346PubMedCrossRefGoogle Scholar
  59. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D, Zhang M (2001) Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 61:6945–6951PubMedGoogle Scholar
  60. Shi HY, Zhang W, Liang R, Kittrell F, Templeton NS, Medina D, Zhang M (2003) Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol 18:201–206PubMedGoogle Scholar
  61. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271–278PubMedCrossRefGoogle Scholar
  62. Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, Ali-Fehmi R (2006) Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101:385–389PubMedCrossRefGoogle Scholar
  63. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T (1994) Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77:829–839PubMedCrossRefGoogle Scholar
  64. Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM, Ozato K (2004) Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol 172:6820–6827PubMedGoogle Scholar
  65. Tzeng YJ, Guhl E, Graessmann M, Graessmann A (1993) Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. Oncogene 8:1965–1971PubMedGoogle Scholar
  66. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Naggar A, Hung MC (2000) High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 19:2398–2403PubMedCrossRefGoogle Scholar
  67. Yin S, Li X, Meng Y, Finley RL Jr, Sakr W, Yang H, Reddy N, Sheng S (2005) Tumor suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem 280(41):34985–34996PubMedCrossRefGoogle Scholar
  68. Yin S, Lockett J, Meng Y, Biliran H Jr, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J et al (2006) Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 66:4173–4181PubMedCrossRefGoogle Scholar
  69. Zhang M, Maass N, Magit D, Sager R (1997a) Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 8:179–186PubMedGoogle Scholar
  70. Zhang M, Magit D, Botteri F, Shi Y, He K, Li M, Furth P, Sager R (1999) Maspin plays an important role in mammary gland development. Dev Biol 215:278–287PubMedCrossRefGoogle Scholar
  71. Zhang M, Magit D, Sager R (1997b) Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci USA 94:5673–5678PubMedCrossRefGoogle Scholar
  72. Zhang M, Shi Y, Magit D, Furth PA, Sager R (2000a) Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 19:6053–6058PubMedCrossRefGoogle Scholar
  73. Zhang M, Volpert O, Shi YH, Bouck N (2000b) Maspin is an angiogenesis inhibitor. Nat Med 6:196–199PubMedCrossRefGoogle Scholar
  74. Zhang W, Shi HY, Zhang M (2005) Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 5:50PubMedCrossRefGoogle Scholar
  75. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R (1994) Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells [see comments]. Science 263:526–529PubMedCrossRefGoogle Scholar
  76. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S (2000) p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275:6051–6054PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Molecular Pharmacology and Biological ChemistryNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer CenterChicagoUSA

Personalised recommendations